Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 0.30 | 0.01 | 0.00 |
| FCF Yield | -26.58% | -26.69% | -29.41% | -74.76% |
| EV / EBITDA | -0.55 | -0.98 | -0.55 | 0.93 |
| Quality | ||||
| ROIC | -8.62% | -9.15% | -8.52% | -16.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.93 | 0.88 | 0.92 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,897,773.89% | 1,897,773.89% | 944.44% | 728.97% |
| Free Cash Flow Growth | -0.13% | 9.02% | 56.46% | -9.17% |
| Safety | ||||
| Net Debt / EBITDA | 2.55 | 1.83 | 2.28 | 1.99 |
| Interest Coverage | 23,798.00 | -26,081.00 | -12,959.50 | 4,902.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -35.18 |